Role of Angiotensin Converting Enzyme Inhibitor on the Functional Changes in Irradiated Rates

2005 ◽  
Vol 35 (4) ◽  
pp. 983-994
Author(s):  
Samia Elewa ◽  
Amel El-Sawaf ◽  
Yossriya El-Sayed ◽  
Abd El-Aziz Belal
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Angiotensin Converting Enzyme Inhibitor ◽  
Enzyme Inhibitor ◽  
Converting Enzyme ◽  
Functional Changes ◽  
Converting Enzyme Inhibitor

scholarly journals Residual Renal Function in Hemodialysis Patients: The Role of Angiotensin-Converting Enzyme Inhibitor in Its Preservation

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Dimitris Xydakis ◽  
Apostolos Papadogiannakis ◽  
Maria Sfakianaki ◽  
Konstantinos Kostakis ◽  
Konstantinos Stylianou ◽  
...  
Keyword(s):  
Renal Function ◽  
Angiotensin Converting Enzyme ◽  
Angiotensin Converting Enzyme Inhibitor ◽  
Enzyme Inhibitor ◽  
Residual Renal Function ◽  
Hemodialysis Patients ◽  
Morbidity And Mortality ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitor

Residual Renal function (RRF) has an important role in the overall morbidity and mortality in hemodialysis patients. The role of angiotensin-converting enzyme inhibitor (ACEi) in preserving renal function in chronic proteinuric nephropathies is well documented. We test the hypothesis that enalapril (an ACEi) slows the rate of decline of RRF in patients starting hemodialysis. A prospective, randomized open-label study was carried out. 42 patients were randomized in two groups either in treatment with enalapril or no treatment at all. Our study has proven that enalapril has a significant effect on preserving residual renal function in patients starting dialysis at least during the first 12 months from the initiation of the hemodialysis. Further studies are necessary in order to investigate the potential long-term effect of ACEi on residual renal function and on morbidity and mortality in patients starting hemodialysis.

Sign in / Sign up

Export Citation Format

Share Document